Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.

@article{Cornel2016EffectOS,
  title={Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.},
  author={Jan Hein Cornel and George L Bakris and Susanna R. Stevens and Michael Alvarsson and Willem A. Bax and Lee-Ming Chuang and Samuel S Engel and Renato D Lopes and Darren K McGuire and Axel Riefflin and Helena W Rodbard and Isaac R. Sinay and Tsvetalina Tankova and Julio Wainstein and Eric D. Peterson and Rury R Holman},
  journal={Diabetes care},
  year={2016},
  volume={39 12},
  pages={2304-2310}
}
OBJECTIVE To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials.gov) participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase 4 inhibitor, according to baseline estimated glomerular filtration rate (eGFR). RESEARCH DESIGN AND METHODS We used data from 14,671 TECOS participants assigned in a double-blind design to receive sitagliptin or placebo added to existing… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…